We may be a step closer to a highly effective mRNA vaccine against HIV, but tests so far reveal that the approach can cause ...

Q2 2025 Earnings Call Transcript August 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.13, ...

Despite a net loss, Moderna Inc (MRNA) showcases resilience with significant cost cuts, new FDA approvals, and a robust cash ...

A team from the Max-Planck-Institut für Kohlenforschung, Hokkaido University, and Osaka University has discovered that subtle ...

HIV vaccine efforts have been slowed by the difficulty of getting neutralizing antibodies to target the correct locations of ...

A breakthrough in our understanding of mRNA delivery systems in the body may allow for more direct treatments for ...

Results from early-stage trial show that 80% of participants who received one of two HIV vaccine candidates produced antibodies against viral proteins.

Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...

Researchers at Harvard Medical School and Brigham and Women's Hospital designed an ingestible capsule that delivers liquid ...

What if mRNA vaccines could be made more powerful and less irritating? Scientists at the University of Pennsylvania have ...

Heart attacks remain a leading cause of death and disability worldwide. The permanent loss of heart muscle cells—known as ...

The results suggest the possibility of a vaccine for HIV/AIDS, which killed more than half a million people last year.